Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease

A new look at the statistical model identification

Akaike, H. (1974) · IEEE Transactions on Automatic Control · doi:10.1109/tac.1974.1100705 · Cited by 51,879 · see citing works

The Clinical Dementia Rating (CDR): Current version and scoring rules

Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882 · see citing works

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · see citing works

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396 · see citing works

Automatically Parcellating the Human Cerebral Cortex

Fischl, B. R. (2003) · Cerebral Cortex · doi:10.1093/cercor/bhg087 · Cited by 4,208 · see citing works

A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume

Buckner, R. L., Head, D. M., Parker, J. B., Fotenos, A. F., Marcus, D. S., Morris, J. C., & Snyder, A. Z. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.06.018 · Cited by 1,290 · see citing works

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ ₄₂ in humans

Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246 · see citing works

[ ¹¹ C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease

Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036 · see citing works

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833 · see citing works

Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease

Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661 · see citing works

An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease

Jack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22628 · Cited by 602 · see citing works

Disruption of the Sleep-Wake Cycle and Diurnal Fluctuation of β-Amyloid in Mice with Alzheimer’s Disease Pathology

Roh, J. H., Huang, Y., Bero, A. W., Kasten, T., Stewart, F. R., Bateman, R. J., & Holtzman, D. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004291 · Cited by 563 · see citing works

Relationships between biomarkers in aging and dementia

Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., Foster, N. L., Petersen, R. C., Weiner, M. W., Price, J. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc010c · Cited by 456 · see citing works

Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation

Villeneuve, S., Rabinovici, G. D., Cohn-Sheehy, B. I., Madison, C., Ayakta, N., Ghosh, P. M., La Joie, R., Arthur-Bentil, S. K., Vogel, J. W., Marks, S. M., et al. (2015) · Brain · doi:10.1093/brain/awv112 · Cited by 408 · see citing works

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

Palmqvist, S., Mattsson, N., Hansson, O., & Initiative, F. T. A. D. N. (2016) · Brain · doi:10.1093/brain/aww015 · Cited by 400 · see citing works

Contribution of Alzheimer disease to mortality in the United States

James, B. D., Leurgans, S. E., Hebert, L. E., Scherr, P. A., Yaffe, K. S., & Bennett, D. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000240 · Cited by 364 · see citing works

Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease

Fagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900048 · Cited by 353 · see citing works

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age

Sutphen, C. L., Jasielec, M. S., Shah, A. R., Macy, E. M., Xiong, C., Vlassenko, A. G., Benzinger, T. L. S., Stoops, E., Vanderstichele, H., Brix, B., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1285 · Cited by 294 · see citing works

Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid

Grimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Shiga, T., Wester, H.-J., Kurz, A., & Drzezga, A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.027 · Cited by 278 · see citing works

Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease

Ng, S., Villemagne, V. L., Berlangieri, S. U., Lee, S.-T., Cherk, M. H., Gong, S., Ackermann, U., Saunder, T., Tochon‐Danguy, H., Jones, G. R., et al. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037762 · Cited by 258 · see citing works

Where, when, and in what form does sporadic Alzheimerʼs disease begin?

Braak, H., & Tredici, K. D. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32835a3432 · Cited by 252 · see citing works

Partial volume correction in quantitative amyloid imaging

Su, Y., Blazey, T. M., Snyder, A. Z., Raichle, M. E., Marcus, D. S., Ances, B. M., Bateman, R. J., Cairns, N. J., Aldea, P., Cash, L., et al. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2014.11.058 · Cited by 247 · see citing works

Quantitative Analysis of PiB-PET with FreeSurfer ROIs

Su, Y., D'Angelo, G. M., Vlassenko, A. G., Zhou, G., Snyder, A. Z., Marcus, D. S., Blazey, T. M., Christensen, J. J., Vora, S., Morris, J. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073377 · Cited by 246 · cited 1× · see citing works

Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers

Potter, R., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T., Sigurdson, W., Mawuenyega, K., Blazey, T., Goate, A., Chott, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005615 · Cited by 236 · see citing works

Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide.

Maggio, J. E., Stimson, E. R., Ghilardi, J. R., Allen, C. J., Dahl, C. E., Whitcomb, D. C., Vigna, S. R., Vinters, H. V., Labenski, M. E., & Mantyh, P. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5462 · Cited by 194 · see citing works

Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant

Mormino, E. C., Brandel, M. G., Madison, C. M., Rabinovici, G. D., Marks, S., Baker, S. L., & Jagust, W. J. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.07.098 · Cited by 158 · see citing works

Amyloid‐beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data

Vlassenko, A. G., Mintun, M. A., Xiong, C., Sheline, Y. I., Goate, A., Benzinger, T. L. S., & Morris, J. C. (2011) · Annals of Neurology · doi:10.1002/ana.22608 · Cited by 144 · see citing works

Harmonized diagnostic criteria for Alzheimer's disease: recommendations

Morris, J. C., Blennow, K., Froelich, L., Nordberg, A. K., Soininen, H. S., Waldemar, G., Wahlund, L., & Dubois, B. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12199 · Cited by 120 · see citing works

Dynamic Analysis of Amyloid β-Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal Aβ during Age-Related Plaque Formation

Hong, S., Quintero-Monzon, O., Ostaszewski, B. L., Podlisny, D. R., Cavanaugh, W. T., Yang, T., Holtzman, D. M., Cirrito, J. R., & Selkoe, D. J. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3272-11.2011 · Cited by 111 · see citing works

Longitudinal Patterns of β-Amyloid Deposition in Nondemented Older Adults

Sojkova, J., Zhou, Y., An, Y., Kraut, M. A., Ferrucci, L., Wong, D. F., & Resnick, S. M. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.77 · Cited by 99 · see citing works

Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches

Cohen, A. D., Mowrey, W. B., Weissfeld, L. A., Aizenstein, H. J., McDade, E., Mountz, J. M., Nebes, R. D., Saxton, J. A., Snitz, B. E., DeKosky, S. T., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.01.015 · Cited by 97 · see citing works

Cognitive profiles in dementia

Johnson, D. K., Storandt, M., Morris, J. C., Langford, Z. D., & Galvin, J. E. (2008) · Neurology · doi:10.1212/01.wnl.0000335972.35970.70 · Cited by 73 · see citing works

Demographic Influences on Free and Cued Selective Reminding Performance in Older Persons

Grober, E. H., Lipton, R. B., Katz, M. J., & Sliwinski, M. J. (1998) · Journal of Clinical and Experimental Neuropsychology · doi:10.1076/jcen.20.2.221.1177 · Cited by 39 · see citing works

Effects of Aging and Alzheimer's Disease Along the Longitudinal Axis of the Hippocampus

Gordon, B. A., Blazey, T., Benzinger, T. L. S., & Head, D. M. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130011 · Cited by 38 · see citing works

Physical Activity and Cognitive Trajectories in Cognitively Normal Adults

Pizzie, R. G., Hindman, H., Roe, C. M., Head, D. M., Grant, E., Morris, J. C., & Hassenstab, J. J. (2013) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31829628d4 · Cited by 35 · see citing works

NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · see citing works

Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model

Spangenberg, E., Severson, P. L., Hohsfield, L. A., Crapser, J., Zhang, J., Burton, E. A., Zhang, Y., Spevak, W., Lin, J., Phan, N. Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11674-z · Cited by 939 · see citing works

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885 · see citing works

Tau PET imaging in neurodegenerative tauopathies—still a challenge

Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0342-8 · Cited by 628 · see citing works

Circadian rest-activity pattern changes in aging and preclinical Alzheimer disease

Musiek, E. S., Bhimasani, M., Zangrilli, M. A., Morris, J. C., Holtzman, D. M., & Ju, Y.-E. S. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4719 · Cited by 465 · see citing works

Gut microbiome composition may be an indicator of preclinical Alzheimer’s disease

Ferreiro, A. L., Choi, J., Ryou, J., Newcomer, E. P., Thompson, R., Bollinger, R. M., Hall-Moore, C. M., Ndao, I. M., Sax, L., Benzinger, T. L. S., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abo2984 · Cited by 369 · see citing works

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

Salloway, S., Farlow, M., McDade, E., Clifford, D. B., Wang, G., Llibre-Guerra, J. J., Hitchcock, J. M., Mills, S. L., Santacruz, A. M., Aschenbrenner, A. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01369-8 · Cited by 359 · see citing works

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

Palmqvist, S., Insel, P. S., Stomrud, E., Janelidze, S., Zetterberg, H., Brix, B., Eichenlaub, U., Dage, J. L., Chai, X., Blennow, K., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201911170 · Cited by 353 · see citing works

Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition

Mosconi, L., Berti, V., Dyke, J. P., Schelbaum, E., Jett, S., Loughlin, L., Jang, G., Rahman, A., Hristov, H., Pahlajani, S. S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90084-y · Cited by 313 · see citing works

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

Lewczuk, P., Riederer, P. F., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramı́rez, A., Parnetti, L., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 308 · see citing works

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging

Schindler, S. E., Gray, J. D., Gordon, B. A., Xiong, C., Batrla‐Utermann, R., Quan, M., Wahl, S., Benzinger, T. L. S., Holtzman, D. M., Morris, J. C., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.013 · Cited by 284 · see citing works

Cerebrospinal Fluid Aβ 42/40 Corresponds Better than Aβ 42 to Amyloid PET in Alzheimer’s Disease

Lewczuk, P., Matzen, A., Blennow, K., Parnetti, L., Molinuevo, J. L., Eusebi, P., Kornhuber, J., Morris, J. C., & Fagan, A. M. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160722 · Cited by 263 · see citing works

Association of Preclinical Alzheimer Disease With Optical Coherence Tomographic Angiography Findings

O’Bryhim, B. E., Apte, R. S., Kung, N. H., Coble, D. W., & Stavern, G. P. V. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.3556 · Cited by 249 · see citing works

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's <i>continuum</i>

Milà‐Alomà, M., Salvadó, G., Gispert, J. D., Vilor‐Tejedor, N., Grau‐Rivera, O., Sala‐Vila, A., Sánchez‐Benavides, G., Arenaza‐Urquijo, E. M., Crous‐Bou, M., González‐de‐Echávarri, J. M., et al. (2020) · Alzheimer's &amp; Dementia · doi:10.1002/alz.12131 · Cited by 241 · see citing works

Staging <b>β</b> -Amyloid Pathology With Amyloid Positron Emission Tomography

Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J., & Hansson, O. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2214 · Cited by 237 · see citing works

Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers

Gordon, B. A., Blazey, T. M., Christensen, J., Dincer, A., Flores, S., Keefe, S., Chen, C., Su, Y., McDade, E. M., Wang, G., et al. (2019) · Brain · doi:10.1093/brain/awz019 · Cited by 180 · see citing works

Persistent metabolic youth in the aging female brain

Goyal, M. S., Blazey, T., Su, Y., Couture, L. E., Durbin, T. J., Bateman, R. J., Benzinger, T. L. S., Morris, J. C., Raichle, M. E., & Vlassenko, A. G. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815917116 · Cited by 178 · see citing works

Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype

Mishra, S., Blazey, T. M., Holtzman, D. M., Cruchaga, C., Su, Y., Morris, J. C., Benzinger, T. L. S., & Gordon, B. A. (2018) · Brain · doi:10.1093/brain/awy103 · Cited by 151 · see citing works

Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light

Schindler, S. E., Karikari, T. K., Ashton, N. J., Henson, R. L., Yarasheski, K. E., West, T., Meyer, M. R., Kirmess, K. M., Li, Y., Saef, B. A., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200358 · Cited by 140 · see citing works

Comparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies

Su, Y., Flores, S. E., Wang, G., Hornbeck, R. C., Speidel, B. A., Joseph‐Mathurin, N., Vlassenko, A. G., Gordon, B. A., Koeppe, R. A., Klunk, W. E., et al. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.12.008 · Cited by 140 · see citing works

Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies

Su, Y., Flores, S., Hornbeck, R. C., Speidel, B., Vlassenko, A. G., Gordon, B. A., Koeppe, R. A., Klunk, W. E., Xiong, C., Morris, J. C., et al. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.04.022 · Cited by 126 · see citing works

Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years

Albert, M., Zhu, Y., Moghekar, A., Mori, S., Miller, M. I., Soldan, A., Pettigrew, C., Selnes, O., Li, S., & Wang, M.-C. (2018) · Brain · doi:10.1093/brain/awx365 · Cited by 118 · see citing works

Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy

Charidimou, A., Friedrich, J. O., Greenberg, S. M., & Viswanathan, A. (2018) · Neurology · doi:10.1212/wnl.0000000000005030 · Cited by 118 · see citing works

Detectable Neuropsychological Differences in Early Preclinical Alzheimer’s Disease: A Meta-Analysis

Han, D.-K. S., Nguyen, C. P., Stricker, N., & Nation, D. (2017) · Neuropsychology Review · doi:10.1007/s11065-017-9345-5 · Cited by 103 · see citing works

Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease

Vlassenko, A. G., Gordon, B. A., Goyal, M. S., Su, Y., Blazey, T. M., Durbin, T. J., Couture, L. E., Christensen, J. J., Jafri, H., Morris, J. C., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.03.014 · Cited by 107 · see citing works

Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET

Schindler, S. E., Li, Y., Buckles, V. D., Gordon, B. A., Benzinger, T. L. S., Wang, G., Coble, D., Klunk, W. E., Fagan, A. M., Holtzman, D. M., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012775 · Cited by 86 · see citing works

Long-term prognosis and educational determinants of brain network decline in older adult individuals

Chan, M. Y., Han, L., Carreno, C. A., Zhang, Z., Rodriguez-Boerwinkle, R. M., LaRose, M., Hassenstab, J. J., & Wig, G. S. (2021) · Nature Aging · doi:10.1038/s43587-021-00125-4 · Cited by 92 · see citing works

Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset

Li, Y., Yen, D., Hendrix, R. D., Gordon, B. A., Dlamini, S. L., Barthélemy, N. R., Aschenbrenner, A. J., Henson, R. L., Herries, E. M., Volluz, K., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26891 · Cited by 86 · see citing works

Cross‐sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology

Gordon, B. A., McCullough, A. A., Mishra, S., Blazey, T., Su, Y., Christensen, J., Dincer, A., Jackson, K., Hornbeck, R. C., Morris, J. C., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.02.003 · Cited by 86 · see citing works

Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer’s disease

Sung, Y. J., Yang, C., Norton, J., Johnson, M., Fagan, A., Bateman, R. J., Perrin, R. J., Morris, J. C., Farlow, M. R., Chhatwal, J. P., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq5923 · Cited by 84 · see citing works

Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: A systematic critical update

Farid, K., Charidimou, A., & Baron, J. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.05.002 · Cited by 83 · see citing works

Concordance of Lumipulse cerebrospinal fluid t‐tau/Aβ42 ratio with amyloid PET status

Kaplow, J., Vandijck, M., Gray, J., Kanekiyo, M., Huyck, E., Traynham, C. J., Esquivel, R., Fagan, A. M., & Luthman, J. (2020) · Alzheimer's &amp; Dementia · doi:10.1002/alz.12000 · Cited by 81 · see citing works

Amyloid-PET in sporadic cerebral amyloid angiopathy

Charidimou, A., Farid, K., & Baron, J. (2017) · Neurology · doi:10.1212/wnl.0000000000004539 · Cited by 75 · see citing works

Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study

Millar, P. R., Gordon, B. A., Luckett, P. H., Benzinger, T. L. S., Cruchaga, C., Fagan, A. M., Hassenstab, J. J., Perrin, R. J., Schindler, S. E., Allegri, R., et al. (2023) · eLife · doi:10.7554/elife.81869 · Cited by 72 · see citing works

Associations Between β-Amyloid Kinetics and the β-Amyloid Diurnal Pattern in the Central Nervous System

Lucey, B. P., Mawuenyega, K. G., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T. P., Morris, J. C., & Bateman, R. J. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.4202 · Cited by 69 · see citing works

PET molecular imaging for pathophysiological visualization in Alzheimer’s disease

Wang, J., Jin, C., Zhou, J., Zhou, R., Tian, M., Lee, H. J., & Zhang, H. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05999-z · Cited by 66 · see citing works

Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer’s disease

Guo, T., Korman, D., Joie, R. L., Shaw, L. M. J., Trojanowski, J. Q., Jagust, W. J., Landau, S. M., & Initiative, A. D. N. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00665-8 · Cited by 66 · see citing works

Widespread distribution of tauopathy in preclinical Alzheimer's disease

Schultz, S. A., Gordon, B. A., Mishra, S., Su, Y., Perrin, R. J., Cairns, N. J., Morris, J. C., Ances, B. M., & Benzinger, T. L. S. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.022 · Cited by 63 · see citing works

Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease

Brown, B. M., Sohrabi, H. R., Taddei, K., Gardener, S. L., Rainey‐Smith, S. R., Peiffer, J. J., Xiong, C., Fagan, A. M., Benzinger, T. L. S., Buckles, V., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.03.008 · Cited by 63 · see citing works

Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance

Charidimou, A., Farid, K., Tsai, H.-H. C., Tsai, L., Yen, R., & Baron, J. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316851 · Cited by 63 · see citing works

Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease

Millar, P. R., Luckett, P. H., Gordon, B. A., Benzinger, T. L. S., Schindler, S. E., Fagan, A. M., Cruchaga, C., Bateman, R. J., Allegri, R., Jucker, M., et al. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119228 · Cited by 59 · see citing works

Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease

Schultz, S. A., Strain, J. F., Adedokun, A., Wang, Q., Preische, O., Kühle, J., Flores, S. E., Keefe, S., Dincer, A., Ances, B. M., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104960 · Cited by 57 · see citing works

Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ42 and T-Tau assays for Alzheimer’s disease diagnosis

Bayart, J., Hanseeuw, B. J., Ivanoiu, A., & Pesch, V. V. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09418-6 · Cited by 55 · see citing works

Molecular‐based diagnosis of multiple sclerosis and its progressive stage

Barbour, C. R., Kosa, P. F., Komori, M., Tanigawa, M., Masvekar, R. R., Wu, T., Johnson, K. R., Douvaras, P., Fossati, V., Herbst, R., et al. (2017) · Annals of Neurology · doi:10.1002/ana.25083 · Cited by 54 · see citing works

Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults

Li, G., Shofer, J. B., Petrie, E. C., Yu, C., Wilkinson, C. W., Figlewicz, D. P., Shutes‐David, A., Zhang, J., Montine, T. J., Raskind, M. A., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0271-9 · Cited by 53 · see citing works

Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults

Guo, T., Shaw, L. M. J., Trojanowski, J. Q., Jagust, W. J., Landau, S. M., & Initiative, A. D. N. (2020) · Neurology · doi:10.1212/wnl.0000000000010596 · Cited by 51 · see citing works

Association of amyloid-β CSF/PET discordance and tau load 5 years later

Reimand, J., Collij, L. E., Scheltens, P., Bouwman, F. H., Ossenkoppele, R., & Initiative, A. D. N. (2020) · Neurology · doi:10.1212/wnl.0000000000010739 · Cited by 49 · see citing works

Preclinical Alzheimer’s disease biomarkers accurately predict cognitive and neuropathological outcomes

Long, J. M., Coble, D. W., Xiong, C., Schindler, S. E., Perrin, R. J., Gordon, B. A., Benzinger, T. L. S., Grant, E., Fagan, A. M., Harari, O., et al. (2022) · Brain · doi:10.1093/brain/awac250 · Cited by 46 · see citing works

Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab

Liu, E., Wang, D., Sperling, R. A., Salloway, S., Fox, N. C., Blennow, K., Scheltens, P., Schmidt, M. E., Streffer, J. R., Novak, G., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005060 · Cited by 42 · see citing works

Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers

Roe, C. M., Ances, B. M., Head, D. M., Babulal, G. M., Stout, S. H., Grant, E., Hassenstab, J. J., Xiong, C., Holtzman, D. M., Benzinger, T. L. S., et al. (2018) · Brain · doi:10.1093/brain/awy244 · Cited by 40 · see citing works

Increased Inflammation and Unchanged Density of Synaptic Vesicle Glycoprotein 2A (SV2A) in the Postmortem Frontal Cortex of Alzheimer’s Disease Patients

Metaxas, A., Thygesen, C., Briting, S. R. R., Landau, A. M., Darvesh, S., & Finsen, B. R. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00538 · Cited by 41 · see citing works

Amyloid‐ β PET and CSF in an autopsy‐confirmed cohort

Reimand, J., Boon, B. D. C., Collij, L. E., Teunissen, C. E., Rozemüller, A. J. M., van Berckel, B. N. M., Scheltens, P., Ossenkoppele, R., & Bouwman, F. H. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51195 · Cited by 38 · see citing works

Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals

Tijms, B. M., Vermunt, L., Zwan, M. D., van Harten, A. C., van der Flier, W. M., Teunissen, C. E., Scheltens, P., Visser, P. J., & for, A. D. N. I. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.615 · Cited by 37 · see citing works

Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: From biological biomarkers to clinical syndromes

Carandini, T., Arighi, A., Sacchi, L., Fumagalli, G. G., Pietroboni, A. M., Ghezzi, L., Colombi, A., Scarioni, M., Fenoglio, C., De Riz, M. A., et al. (2019) · Alzheimer's Research &amp; Therapy · doi:10.1186/s13195-019-0543-7 · Cited by 36 · see citing works

Evaluating resting-state BOLD variability in relation to biomarkers of preclinical Alzheimer's disease

Millar, P. R., Ances, B. M., Gordon, B. A., Benzinger, T. L. S., Fagan, A. M., Morris, J. C., & Balota, D. A. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.08.007 · Cited by 33 · see citing works

Sex and menopause impact 31P-Magnetic Resonance Spectroscopy brain mitochondrial function in association with 11C-PiB PET amyloid-beta load

Jett, S., Dyke, J. P., Andy, C., Schelbaum, E., Jang, G., Boneu, C., Pahlajani, S. S., Diaz, I., Brinton, R. D., & Mosconi, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-26573-5 · Cited by 29 · see citing works

12-year prediction of mild cognitive impairment aided by Alzheimer’s brain signatures at mean age 56

Williams, M. E., Elman, J. A., McEvoy, L. K., Andreassen, O. A., Dale, A. M., Eglit, G. M. L., Eyler, L. T., Fennema‐Notestine, C., Franz, C. E., Gillespie, N. A., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab167 · Cited by 28 · see citing works

Macular Microvascular Density as a Diagnostic Biomarker for Alzheimer’s Disease

Wang, X., Wang, Y., Liu, H., Zhu, X., Hao, X., Zhu, Y., Xu, B., Zhang, S., Jia, X., Weng, L., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220482 · Cited by 28 · see citing works

Pupillary light reaction in preclinical Alzheimer’s disease subjects compared with normal ageing controls

Stavern, G. P. V., Bei, L., Shui, Y., Huecker, J. B., & Gordon, M. E. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-312425 · Cited by 25 · see citing works

Amyloid and Tau in Alzheimer’s Disease: Biomarkers or Molecular Targets for Therapy? Are We Shooting the Messenger?

Kumar, A., Nemeroff, C. B., Cooper, J. J., Widge, A. S., Rodríguez, C. I., Carpenter, L. L., & McDonald, W. M. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.19080873 · Cited by 25 · see citing works

Cerebrospinal fluid dynamics and discordant amyloid biomarkers

Graff‐Radford, J., Jones, D. T., Wiste, H. J., Cogswell, P. M., Weigand, S. D., Lowe, V. J., Elder, B. D., Vemuri, P., van Harten, A. C., Mielke, M. M., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.10.017 · Cited by 24 · see citing works

Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk

Ali, M., Sung, Y. J., Wang, F., Fernández, M. V., Morris, J. C., Fagan, A. M., Blennow, K., Zetterberg, H., Heslegrave, A., Johansson, P., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267298 · Cited by 23 · see citing works

Reductions in the white–gray functional connectome in preclinical Alzheimer's disease and their associations with amyloid and cognition

Xu, L., Zhao, Y., Choi, S., Li, M., Schilling, K. G., Zu, Z., Rogers, B. P., Ding, Z., Anderson, A. W., Landman, B. A., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14334 · Cited by 19 · see citing works

Establishment of combined diagnostic models of Alzheimer’s disease in a Chinese cohort: the Chongqing Ageing & Dementia Study (CADS)

Fan, D., Jian, J.-M., Huang, S., Li, W., Shen, Y., Wang, Z., Zeng, G., Yi, X., Jin, W., Liu, Y.-H., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02016-7 · Cited by 19 · see citing works

Urine dicarboxylic acids change in pre-symptomatic Alzheimer’s disease and reflect loss of energy capacity and hippocampal volume

Castor, K., Shenoi, S., Edminster, S. P., Tran, T. T., King, K. S., Chui, H. C., Pogoda, J. M., Fonteh, A. N., & Harrington, M. G. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231765 · Cited by 21 · see citing works

Phosphorus metabolism in the brain of cognitively normal midlife individuals at risk for Alzheimer's disease

Parasoglou, P., Osorio, R. S., Khegai, O., Kovbasyuk, Z., Miller, M. D., Ho, A., Dehkharghani, S., Wısnıewskı, T., Convit, A. J., Mosconi, L., et al. (2022) · Neuroimage Reports · doi:10.1016/j.ynirp.2022.100121 · Cited by 18 · see citing works

Plasma Biomarkers as Predictors of Progression to Dementia in Individuals with Mild Cognitive Impairment

Nallapu, B. T., Initiative, T. A. D. N., Petersen, K. K., Lipton, R. B., Davatzikos, C. A., & Ezzati, A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230620 · Cited by 17 · see citing works

Association of Acquired and Heritable Factors With Intergenerational Differences in Age at Symptomatic Onset of Alzheimer Disease Between Offspring and Parents With Dementia

Day, G. S., Cruchaga, C., Wingo, T. S., Schindler, S. E., Coble, D. W., & Morris, J. C. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.13491 · Cited by 17 · see citing works

Elevated locus coeruleus metabolism provides resilience against cognitive decline in preclinical Alzheimer's disease

Koops, E. A., Dutta, J., Hanseeuw, B. J., Becker, J. A., Egroo, M. V., Prokopiou, P. C., Price, J. C., Arnold, S. E., Sperling, R. A., Johnson, K. A., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14385 · Cited by 16 · see citing works

Analysis of longitudinal diffusion-weighted images in healthy and pathological aging: An ADNI study

Kruggel, F., Masaki, F., & Solodkin, A. (2017) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2016.12.020 · Cited by 15 · see citing works

Optimal Combinations of AT(N) Biomarkers to Determine Longitudinal Cognition in the Alzheimer's Disease

Lin, R.-R., Xue, Y., Li, X., Chen, Y.-H., Tao, Q., & Wu, Z. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.718959 · Cited by 15 · see citing works

A flexible modeling approach for biomarker‐based computation of absolute risk of Alzheimer's disease dementia

Hartz, S. M., Mozersky, J. T., Schindler, S. E., Linnenbringer, E. L., Wang, J., Gordon, B. A., Raji, C. A., Moulder, K. L., West, T., Benzinger, T. L. S., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12781 · Cited by 10 · see citing works

Serum metabolome profiling in patients with mild cognitive impairment reveals sex differences in lipid metabolism

Escarcega, R. D., J., V. K. M., Kyriakopoulos, V. E., Ortiz, G. J., Gusdon, A. M., Fan, H., Peesh, P., Conesa, M. P. B., Colpo, G. D., Ahnstedt, H. W., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106747 · Cited by 11 · see citing works

Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice

Echeveste, B., Prieto, E., Guillén, E. F., Jimenez, A., Montoya‐Murillo, G., Villino‐Rodríguez, R. A., Riverol, M., & Arbizu, J. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07275-2 · Cited by 10 · see citing works

Associations of Stages of Objective Memory Impairment with Cerebrospinal Fluid and Neuroimaging Biomarkers of Alzheimer's Disease

Petersen, K. K., Ezzati, A., Lipton, R. B., Gordon, B. A., Hassenstab, J. J., Morris, J. C., & Grober, E. H. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.98 · Cited by 8 · see citing works

Rust on the Brain from Microbleeds and Its Relevance to Alzheimer Studies: Invited Commentary on Cacciottolo Neurobiology of Aging, 2016

Cacciottolo, M., Morgan, T. E., & Finch, C. E. (2016) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000287 · Cited by 7 · see citing works

Brain Biomarkers in Familial Alzheimer’s Disease Mouse Models

Hirshler, Y., Venkatasubramanian, P. N., Apolinario, J., Bonds, J. A., Wyrwicz, A. M., & Lazarov, O. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170269 · Cited by 7 · see citing works

Amyloid PETs are commonly negative in suspected Alzheimer’s disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study

Manca, C., Jonveaux, T., Roch, V., Marie, P., Karcher, G., Lamiral, Z., Malaplate, C., & Verger, A. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09315-y · Cited by 7 · see citing works

Unravelling the Association Between Amyloid-PET and Cerebrospinal Fluid Biomarkers in the Alzheimer’s Disease Spectrum: Who Really Deserves an A+?

Sacchi, L., Carandini, T., Fumagalli, G., Pietroboni, A. M., Contarino, V. E., Siggillino, S., Arcaro, M., Fenoglio, C., Zito, F., Marotta, G., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210593 · Cited by 6 · see citing works

Neural network training with highly incomplete medical datasets

Chang, Y.-W., Natali, L., Jamialahmadi, O., Romeo, S., Pereira, J. B., & Volpe, G. (2022) · Machine Learning Science and Technology · doi:10.1088/2632-2153/ac7b69 · Cited by 6 · see citing works

Exploring the Link Between Periodontitis and Alzheimer’s Disease—Could a Nanoparticulate Vaccine Break It?

da Silva, A. F., Gomes, A., Gonçalves, L., Fernandes, A. M. A., & Almeida, A. J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020141 · Cited by 4 · see citing works

A multiscale model to explain the spatiotemporal progression of amyloid beta and tau pathology in Alzheimer's disease

Xu, C., Xu, E., Xiao, Y., Yang, D., Guorong Wu, A., & Chen, M. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142887 · Cited by 3 · see citing works

Tau positron emission tomography imaging in C9orf72 repeat expansion carriers

Ly, C. V., Koenig, L., Christensen, J. J., Gordon, B. A., Beaumont, H., Dahiya, S. M., Chen, Y.-H., Su, Y., Nelson, B., Jockel, J., et al. (2019) · European Journal of Neurology · doi:10.1111/ene.13940 · Cited by 3 · see citing works

Biomarqueurs du liquide cérébrospinal dans la maladie d’Alzheimer

Hugon, J., Dumurgier, J., Cognat, E., & Paquet, C. (2018) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30359-0 · Cited by 2 · see citing works

Effect of aldehyde dehydrogenase and alcohol dehydrogenase inhibitors and ethanol on blood and liver ketone bodies in the rat.

Pronko, P. S., Zimatkin, S. M., & Kuz'mich, A. B. (1994) · PubMed · Cited by 2 · see citing works

Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational studyPreprint

Millar, P. R., Gordon, B. A., Luckett, P. H., Benzinger, T. L. S., Cruchaga, C., Fagan, A. M., Hassenstab, J. J., Perrin, R. J., Schindler, S. E., Allegri, R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.25.505251 · Cited by 2 · see citing works

Cerebrospinal Fluid Biomarkers of Alzheimer Disease

Васильевна, Н. К., Shpilyukova, Y. A., Шабалина, А. А., Fedotova, E. Y., & Illarioshkin, S. N. (2025) · Annals of Clinical and Experimental Neurology · doi:10.17816/acen.1185 · Cited by 1 · see citing works

Single‐cell analysis of osmoregulation reveals heterogeneity of aquaporin 4 functionality in human astrocytes

Steenberghen, H., Beuckeleer, S. D., Hellings, N., Somers, V. A., Breedam, E. V., Ponsaerts, P., Nuydens, R., Maurin, H., Larsen, P. H., & Vos, W. H. D. (2024) · Cytometry Part A · doi:10.1002/cyto.a.24905 · Cited by 1 · see citing works

Neural Network Training with Highly Incomplete DatasetsPreprint

Chang, Y., Natali, L., Jamialahmadi, O., Romeo, S., Pereira, J. B., & Volpe, G. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2107.00429 · Cited by 1 · see citing works

Sex, menopause, and Alzheimer’s risk: a 31P-MR spectroscopy study of brain mitochondrial function in association with 11C-PiB PET amyloid-beta loadPreprint

Jett, S., Dyke, J. P., Andy, C., Schelbaum, E., Jang, G., Boneu, C., Pahlajani, S. S., Díaz, I., Brinton, R. D., & Mosconi, L. (2022) · Research Square · doi:10.21203/rs.3.rs-1723651/v1 · Cited by 1 · see citing works

BrainVAE: Exploring the role of white matter BOLD in preclinical Alzheimer’s disease classificationPreprint

Li, Y., Xu, L., Zuo, L., Chang, Y., Ding, Z., Anderson, A. W., Schilling, K. G., Gore, J. C., Gao, Y., & Initiative, T. A. D. N. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.07.652697 · Cited by 1 · see citing works

Comparing the predictive value of plasma p-tau217 and CSF biomarkers (p-tau181, Aβ42) using amyloid positron emission tomography in Alzheimer's continuumPreprint

Azaraein, M. H., Zarrazvand, E., Heydari, F., Asimi, N., Ramezannezhad, E., Rahimipour, D., Janeshin, K., Mahdian, A., Sichani, M. F., Farhadi, S., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7327653/v1 · Cited by 1 · see citing works

Discordance Between Cerebrospinal Fluid Biomarkers and Amyloid Positron Emission Tomography in Alzheimer’s Sheds Light on Clinical Trial Exclusion Criteria

Major, C. K., & Okhravi, H. R. (2021) · Cureus · doi:10.7759/cureus.13481

Prognostic Impact of 18-F-Florbetaben Amyloid PET Imaging in Patients with Isolated Increases in Cerebrospinal Fluid Phospho-Tau Biomarkers: A Longitudinal Study

Jardel, A., Hopes, L., Malaplate, C., Roch, V., Manca, C., Jonveaux, T., & Verger, A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201435

Neuroimaging and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease

Gordon, B. A., Vos, S. J. B., & Fagan, A. M. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0052

Faculty Opinions recommendation of Persistent metabolic youth in the aging female brain.

Nelson, R. J., & Weil, Z. M. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735000495.793556909

Faculty Opinions recommendation of Persistent metabolic youth in the aging female brain.

Tower, J. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735000495.793556694

PET imagining in Alzheimer’s disease

Korol, P. O., Lukashenko, M. S., Щербіна, О. В., Murashko, V. O., & Ivchuk, V. P. (2023) · Ukrainian Journal of Military Medicine · doi:10.46847/ujmm.2023.4(4)-045

Fast Declining Prediction in Alzheimer’s Disease from Early Clinical Assessment

Álvarez‐Sánchez, L., Peretó, M., García, L., Balaguer, Á., Peña‐Bautista, C., Ferré‐González, L., Baquero, M., & Cháfer-Pericas, C. (2024) · Current Neuropharmacology · doi:10.2174/011570159x332930240925095423

New Research on Biomarkers in Alzheimer’s Continuum

Vecchio, I., & Colica, C. (2025) · Reviews on Recent Clinical Trials · doi:10.2174/0115748871331138250114052615

O3‐02–02: Update on the relationship between in vivo amyloid imaging with C‐PIB and CSF Aβ42

Fagan, A. M., Mintun, M. A., Shah, A. R., Mach, R. H., Morris, J. C., & Holtzman, D. M. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.415

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ ₄₂ in humans

Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246 · see citing works

IC–P–054: Relationship between in vivo amyloid imaging with 11C–PIB and CSF Aβ42

Fagan, A. M., Mintun, M. A., Sacco, D., Sheline, Y. I., Shah, A. R., Spinner, M. L., Mach, R. H., Dence, C. S., Morris, J. C., & Holtzman, D. M. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.05.2259

O3–01–07: Relationship between in vivo amyloid imaging with 11C–PIB and CSF Aβ42

Fagan, A. M., Mintun, M. A., Sacco, D., Sheline, Y. I., Shah, A. R., Spinner, M. L., Mach, R. H., Dence, C. S., Morris, J. C., & Holtzman, D. M. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.05.193

Inverse relation between vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans

Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S.-Y., & Holtzman, D. M. (2006)